Biotechnology News

Please read the announcement in PDF Attachment 2026_22_Share_buyback ...

COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...

KØBENHAVN, Danmark, 19. oktober 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 1. september 2026, hvorunder selskabet vil...

Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 CongressData supplements unprecedented two-year data from the trial including a 75%...

OSE Immuno Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

Les résultats de Topline seront présentés par le Pr Federico Cappuzzo, PhD, le 25 octobre 2026 au congrès annuel de l’European Society for Medical Oncology (ESMO) à MadridOSE Immunotherapeutics...

Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead asset and...

Presentations to cover updates across Eikon’s clinical pipeline including:  Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab...

WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the...